# Pharmacy Benefit Managers The middlemen of American drug pricing — companies that administer prescription benefits for insurers and employers, deciding which drugs are covered (formularies), negotiating manufacturer rebates, and setting what pharmacies get paid. Three firms — CVS Caremark ([[CVS Health]]), Express Scripts ([[Cigna]]), and OptumRx ([[UnitedHealth Group]]) — process roughly 80% of U.S. prescriptions. The PBM layer is the answer to the question every page in the [[Big Pharma]] cluster eventually raises: *who actually sets the price you pay at the counter?* ## The Machine The business model runs on opacity. **Rebates**: manufacturers pay PBMs for favorable formulary placement, a percentage of list price — which rewards *higher* list prices and helped drive the insulin spiral documented at [[Eli Lilly]], [[Novo Nordisk]], and [[Sanofi]]. **Spread pricing**: charging the health plan more than the pharmacy is reimbursed and keeping the difference. **Steering**: directing patients to the PBM's own mail-order and specialty pharmacies. **Offshore GPOs**: group purchasing entities (Zinc, Ascent, Emisar) that collect manufacturer fees beyond rebate-disclosure rules. The FTC's interim reports (July 2024, January 2025) documented the Big Three marking up specialty generics — cancer, heart, HIV drugs — by hundreds or thousands of percent at their own pharmacies. Vertical integration completes the loop: each Big Three PBM sits inside a conglomerate that also owns an insurer and pharmacies, so the entity negotiating "on behalf of" payers profits at every node. The GLP-1 formulary wars made the power visible — CVS Caremark dropped [[Eli Lilly]]'s Zepbound for Wegovy in July 2025 (restored October 2026), demonstrating that a PBM decision can move billions in market value with one formulary line. ## The Reckoning (2024–2026) After two decades of immunity, the PBM layer absorbed the most concentrated regulatory assault in the cluster: - **FTC insulin case** (September 2024) — administrative action against all three PBMs and their GPOs for rebate practices that inflated insulin list prices. **Express Scripts settled February 4, 2026** — no fines, but structural commitments (transparency, rebate pass-through) the FTC valued at up to $7 billion over ten years. Caremark and OptumRx cases continue, with CVS negotiating. - **Statutory reform** (February 3, 2026) — the Consolidated Appropriations Act, 2026 carried landmark PBM provisions: **delinking** (flat fees, not price-based compensation), **spread-pricing bans**, rebate pass-through, and contract transparency across Medicare Part D and commercial markets — effective around January 2029. ## The Political Reading PBMs became the one health-industry target both parties, and pharma itself, agreed to attack — which is exactly what makes the episode analytically interesting. [[PhRMA]] spent years funding the "blame the middlemen" narrative to deflect from list prices, and it *worked*: the only structural drug-pricing law since the [[Inflation Reduction Act]] regulates pharma's adversary, not pharma. The [[UnitedHealthcare CEO Shooting]] and its aftermath supercharged the politics — insurer/middleman rage became the safest populism in Washington. The refinement to the products-vs-power frame at [[Big Pharma]]: when "power" finally got attacked, it was the middlemen's power, with manufacturers applauding. Note also what reform timing means: 30-month implementation puts delinking's effects past the 2028 cycle, with the rulemaking fights still to come. ## Connections - [[CVS Health]] / [[UnitedHealth Group]] / [[Cigna]] — The Big Three parents - [[Big Pharma]] / [[PhRMA]] — The blame-shifting campaign that succeeded - [[UnitedHealthcare CEO Shooting]] — The populist accelerant - [[Most-Favored-Nation Drug Pricing Deals]] — The deal-theater track running parallel to real PBM reform - [[Inflation Reduction Act]] — The other structural drug-pricing law ## See also - [[Insulin and the Politics of Drug Pricing]] — a century-old drug priced as a luxury, and the fight over capping it